|| Checking for direct PDF access through Ovid
Background: The metabolic syndrome (MBS) increases the risk of cardiovascular disease in both men and women. This risk is higher in women. The role of statins in the treatment of MBS remains uncertain.Objectives: To evaluate the ability of high dose atorvastatin to modify components of MBSMethods: Age matched women with MBS (n =88, mean age 52.4 ± 9.2 years), recruited from the Women’s Heart Clinic at the University of Rochester and who met the study inclusion criteria were randomly assigned to either 80 mg of atorvastatin or matching placebo (44 in each arm) in a double blinded fashion. The duration of treatment was 12 weeks. Statistical analysis was performed using Students t-test using SAS 9.3 (Cary, NC).Results: At 6 weeks after randomization, there was significant reduction in the mean LDL, triglycerides, CRP, and Apo-B (p <0.0001, 0.0006, 0.01 and <0.0001) respectively in the atorvastatin arm. There was no difference in fasting blood glucose (FBG), serum HDL, serum Leptin, Apo-A1, and platelet activity (p value NS). A trend towards a decrease in waist circumference (WC) in the atorvastatin arm (p 0.05), while no impact in systolic blood pressure (p 0.92) was seen. These differences persisted at 12 weeks after randomization.Conclusion: High dose atorvastatin has an early and significant impact on biomarkers in women with MBS and is not associated with a rise in FBG. The use of statins for primary prevention in this group of patients should be further exploredTable: Lipogenic, Inflammatory Markers at 6 weeks Post Randomization.